Register
Login:
Share:
Email Facebook Twitter

Looking for big risk, big reward investing? See our exclusive Pharma video series from 'Biotech and Money' Watch here

PHARMA: Peter Molloy has a successful track record of profitably recycling old drugs


Sareum Share Chat (SAR)



Share Price: 0.725Bid: 0.70Ask: 0.75Change: 0.00 (0.00%)No Movement on Sareum
Spread: 0.05Spread as %: 7.14%Open: 0.725High: 0.725Low: 0.725Yesterday’s Close: 0.725


Share Discussion for Sareum


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


Ahfam3
Posts: 49
Observation
Opinion:No Opinion
Price:0.725
View Thread (2)
RE: Ahfam3
Thu 15:30
Thank you chaps for your insight. We do seem to be on the edge of some massive upside. Like Thoth I believe Chk1 is in very good hands and with Sierra trying many different combinations they are hell bent on getting it to market in one form or another so we will definetely benefit from this. Also the PARP combo is an exciting avenue and they seem to be pushing one of the majors to partner with so await in positive anticipation to see who this is. Aurora I am as confused as everyone else as we have shown that it works in vivo but Humec are taking far too long for some reason to get it to Phase 1, so I think the placing will be to take it p1 or get it licensed to someone else. With Tyk2 we have seen the effectivness of it against Tofa, SRI are doing something with it and have received US defence funding, I can't see us waiting too long before it is licensed and still believe Tofa owners Pfizer will snap the auto-immune as they already know it's better then theirs, that leaves the cancer which in my opinion will be candidate selected in 2 pathways in Feb and then someone will take one of them and we will probably get the milestone so try it p1 ourselves. All looking fantastic for us eitherway.
 
shepster
Posts: 40
Off Topic
Opinion:No Opinion
Price:0.725
andy MK
Thu 14:46
thanks for the advice on the letter for the AGM, have sorted that from my broker, live and learn on the process as never been to one of the AGM's before.
Like you i hope my small holding (very small compared to you guys i think) will produce a small amount of cream one day soon, the science and progress seems to say it will but it seems to be one step forward and one back.
As others have said Sierra might be a good buyer as they seem more switched on in terms of progressing things through the system, the current share price progress for them backs this up in my opinion.
Thoth2
Posts: 1,717
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:0.725
View Thread (2)
RE: Ahfam3
Thu 14:22
annual report a bit boring. timelines move back as usual (unfortunately long term hold). plus side some movement on aurora.
For me. I am anticiating dividends of c 4p p.a. off Chk1.
Tyk2. Only us and Pfizer jointly inhibiting Tyk2 & Jak1. Pfizer have tox issues. So for Psoriasis & Lupus depending on both pathways I think we may have the gamechanger (no effective drugs, no competition) $8bn market.
Aurora flts3 cures leukaemia in 10 out of ten mice,. there are no cures for cancer, but its pretty close.
so nothing for the traders. but we have already had a transformation to getting in the clinic. We have had validation that we do in fact make best in class molecules. better than AZN, Lilly, who have tried with Chk1. with low toxicity. so no reason to believe our other compounds are not as excellent. the upside is enormous. (cure for cancer & auto immune). scientific excellence seems validated. competitive position (lack of competitors) & patents are strong. just a little patience required next month, next feb. next June. don't know. we will have to wait and see..
Num4
Posts: 1,099
Off Topic
Opinion:No Opinion
Price:0.725
RE: Ahfam3
Thu 14:05
We always here about Tyk2 being popular and John Reader expressed his excitement with this program a while back.
When you look at previous deals for these compounds they have certainly been, dare i say it... "game changing".
For me there is no reason why this can't be licensed at any time, that is Sareums business model afterall. If that happens then it is a happy ending for all.
I seen an interesting comment from someone about Sierra potentially buying Sareum. Never thought of that but it ticks all of the right boxes - they would just need a fundraising to purchase us. From what I've seen to date with Sierra they are great at raising the awareness and development of trials.
Thinking about Tims exit strategy he obviously will be made a multi-millionnaire from the sale but IMO shouldn't try and be greedy and i don't think he will. I think a modest price to sell the company to Sierra is a very viable outcome. They would continue to develop the compounds and then once ready they go straight into the Sierra machine of PR and development.
Afterall how different is life if you have £10million in the bank or £50million. Id imagine not that different.
Then Im also sure Tim would get equity in Sierra so further happy days ahead.
So my message to Tim and John, sell the company to Sierra, you compliment each other with regards to combining strengths, give your LTHs an end to the continued woe's and give yourself less management responsibility and concentrate on what you do best, discover and design compounds to beat cancer.
GL all
AndytheMKDon
Posts: 10,197
Off Topic
Opinion:No Opinion
Price:0.725
Ahfam3
Thu 13:36
Hey buddy. We seem to be awaiting progression on certain compounds which by now should be heading into trials.

As always with SAR it's a waiting game however Chk1 is only weeks away from news upon P1 trials hence I can't see this dwelling around this price for long. Frustrating how Sierra double off the back of progress with Chk1 and we are as flat as witches t!t.

I'm still a tad upset and confused regarding the placing as to me it seemed unnecessary, no doubt somebody will ask them the motive at the AGM.

I was hoping to go to the agm however the gods have conspired against me and I have to be in meetings overseas.

For those wishing to attend simply mail your bank or broker informing them you need a letter outlining your shareholding, they normally need maximum 5 days to prepare it, you then show it and sign in on entry.

I'm keeping the faith here and sit with quite a few shares, I live in the hope that one day cream will float.

GLA. Andy.
potnak
Posts: 774
Off Topic
Opinion:No Opinion
Price:0.725
RE: Ann. Report
Thu 07:55
There is nothing bad in that report but it is designed to cool the PI's down a bit IMO. Nothing bad but nothing to ramp either.
Ahfam3
Posts: 49
Question
Opinion:No Opinion
Price:0.725
Ann. Report
Wed 23:01
Thoth, Andymk, Zylo, Hopkirk what's your take on the annual report.
mathsprof
Posts: 2,290
Off Topic
Opinion:No Opinion
Price:0.725
RE: 2.745 billion shares in issue
Wed 12:31
potnak - It doesn't work like that. The big volume day was the day when it was announced - some forward selling no doubt, and the opportunity to buy at 0.7p for about half an hour.
Today is just an ordinary trading day with no new news and a few extra shares in circulation.
Krone
Posts: 191
Off Topic
Opinion:No Opinion
Price:0.725
Q3
Wed 12:22
Only 22 working days left until the end of Q3.....are we anticipating updates as previously indicated?
Bountykid
Posts: 389
Off Topic
Opinion:No Opinion
Price:0.725
RE: 2.745 billion shares in issue
Wed 12:06
Yep an absolute bumper day today volume wise LOL a humongous 8 mill traded already an. Still a good 4 hrs to go




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.